[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100496288":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":28,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":38,"eligibilityCriteria":39,"healthyVolunteers":34,"sex":40,"minAge":41,"maxAge":7,"enrollmentInfo":42,"targetDuration":7,"studyType":45,"phases":7,"briefSummary":46,"conditions":47,"keywords":7,"overallStatus":49,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Hospital Samaritano Paulista","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"PEDRO DE BARROS E SILVA, MD PhD","CONTACT","551128275000","centrodeestudos@samaritanopaulista.com.br",[15],{"facility":5,"status":7,"city":16,"state":7,"zip":7,"country":17,"countryCode":18,"cosmosGeoPoint":19,"geoPoint":24,"contacts":25},"São Paulo","Brazil","BR",{"type":20,"coordinates":21},"Point",[22,23],-46.63611,-23.5475,{"lat":23,"lon":22},[26],{"name":27,"role":11,"phone":7,"phoneExt":7,"email":7},"Pedro de Barros e Silva, MD, MHS, PHD",{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Pedro Gabriel Melo de Barros e Silva","Director of Clinical Research","100496288","aspire-aub-has2-plus-biomarkers-100496288",false,"NCT05742282","ASPIRE (Aub-haS2 Plus bIomaRkErs)","Validation of the AUB-HAS2 Score in a Brazilian Population and Study of the Additional Impact of Biomarkers in Predicting Perioperative Risk","ASPIRE","Inclusion Criteria:\n\n* Age ≥ 40 years, in the preoperative period of non-cardiac procedures, with expected hospitalization for at least 24 hours postoperatively.\n\nExclusion Criteria:\n\n* Refusal to sign the informed consent form.","ALL","40 Years",{"count":43,"type":44},2500,"ESTIMATED","OBSERVATIONAL","ASPIRE is a prospective, multicenter, observational study that will assess the performance of AUB-HAS2 to predict the occurrence of major adverse cardiovascular events 30-days after a non-cardiac surgery and the additional role of high-sensitivity troponin T and NT-ProBNP biomarkers in the accuracy of different event prediction indexes after non-cardiac procedures.",[48],"Perioperative Medicine","NOT_YET_RECRUITING","2025-05-15",{"date":52,"type":53},"2025-05-20","ACTUAL",{"date":55,"type":44},"2025-06-21",{"date":57,"type":44},"2026-10-30",{"name":5,"class":6},1]